Literature DB >> 17876052

Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma.

Won Kim1, Jung-Hwan Yoon, Jae-Min Jeong, Gi-Jeong Cheon, Tae-Sup Lee, Jong-In Yang, Su-Cheol Park, Hyo-Suk Lee.   

Abstract

Hypoxia stimulates hepatocellular carcinoma (HCC) cell growth via hexokinase (HK) II induction, and alternatively, HK II inhibition induces apoptosis by activating mitochondrial signaling. This study was to investigate whether the induction of HK II by hypoxia is associated with enhanced mitochondrial stability and to confirm the apoptosis-inducing efficacy of HK II inhibitor in an in vivo model of HCC. Mitochondrial stability was examined by treating isolated mitochondria with deoxycholate, a permeability-enhancing agent. Alteration of permeability transition pore complex composition was analyzed by immunoprecipitation and immunoblotting. An in vivo model of HCC was established in C3H mice i.d. implanted with MH134 cells. The antitumor efficacy of i.p. given 3-bromopyruvate (3-BrPA), a HK II inhibitor, was evaluated by measuring tumor volumes and quantifying apoptosis using terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining and (99m)Tc-hydrazinonicotinamide-Annexin V scans. Hypoxia enhanced mitochondrial stability, and this was inhibited by 3-BrPA treatment. In particular, HK II levels in permeability transition pore complex immunoprecipitates were reduced after 3-BrPA treatment. In mice treated with 3-BrPA, mean tumor volumes and tumor volume growth were found to be significantly reduced. Moreover, percentages of terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive cells were significantly increased in 3-BrPA-treated mice, and this apoptosis-inducing efficacy was reflected in vivo by (99m)Tc-hydrazinonicotinamide-Annexin V imaging. Our results show that hypoxia enhances mitochondrial stability via HK II induction and that HK II inhibitor treatment exhibits an in vivo antitumor effect by inducing apoptosis. Therefore, HK II inhibitors may be therapeutically useful for the treatment of advanced infiltrative hypovascular HCCs, which are growing in a hypoxic environment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17876052     DOI: 10.1158/1535-7163.MCT-07-0115

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  51 in total

1.  Hacking hexokinase halts tumor growth.

Authors:  Yongjun Fan; Wei-Xing Zong
Journal:  Cancer Biol Ther       Date:  2008-06-30       Impact factor: 4.742

2.  Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate.

Authors:  Muthusamy Thangaraju; Senthil K Karunakaran; Shiro Itagaki; Elangovan Gopal; Selvakumar Elangovan; Puttur D Prasad; Vadivel Ganapathy
Journal:  Cancer       Date:  2009-10-15       Impact factor: 6.860

3.  Hexokinase II in CD133+ and CD133- hepatoma BEL-7402 Cells.

Authors:  Lei Gong; Zhuqingqing Cui; Xin Yu; Yuhua Wei; Jirun Peng; Xisheng Leng
Journal:  Pathol Oncol Res       Date:  2011-09-10       Impact factor: 3.201

4.  Carbonic anhydrase-IX inhibition enhances the efficacy of hexokinase II inhibitor for hepatocellular carcinoma in a murine model.

Authors:  Eun Ju Cho; Su Jong Yu; Kyungmin Kim; Heki Cho; Young Youn Cho; Yun Bin Lee; Jeong-Hoon Lee; Yoon Jun Kim; Hyewon Youn; Jung-Hwan Yoon
Journal:  J Bioenerg Biomembr       Date:  2019-02-12       Impact factor: 2.945

5.  [Monocarboxylate transporter 1 enhances the sensitivity of breast cancer cells to 3-bromopyruvate in vitro].

Authors:  Qi-Xiang Li; Pei Zhang; Fang Liu; Xian-Zhi Wang; Lu Li; Zhong-Kun Wang; Chen-Chen Jiang; Hai-Lun Zheng; Hao Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-05-20

6.  Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis.

Authors:  Su-jong Yu; Jung-hwan Yoon; Jeong-hoon Lee; Sun-jung Myung; Eun-sun Jang; Min-sun Kwak; Eun-ju Cho; Ja-june Jang; Yoon-jun Kim; Hyo-suk Lee
Journal:  Acta Pharmacol Sin       Date:  2011-06-13       Impact factor: 6.150

7.  Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate.

Authors:  Ayako Nakano; Hirokazu Miki; Shingen Nakamura; Takeshi Harada; Asuka Oda; Hiroe Amou; Shiro Fujii; Kumiko Kagawa; Kyoko Takeuchi; Shuji Ozaki; Toshio Matsumoto; Masahiro Abe
Journal:  J Bioenerg Biomembr       Date:  2012-02       Impact factor: 2.945

Review 8.  The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside.

Authors:  J Azevedo-Silva; O Queirós; F Baltazar; S Ułaszewski; A Goffeau; Y H Ko; P L Pedersen; A Preto; M Casal
Journal:  J Bioenerg Biomembr       Date:  2016-07-25       Impact factor: 2.945

Review 9.  Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication.

Authors:  Minjong Lee; Jung-Hwan Yoon
Journal:  World J Biol Chem       Date:  2015-08-26

10.  Hexokinase 2 overexpression promotes the proliferation and survival of laryngeal squamous cell carcinoma.

Authors:  Jian Chen; Sulin Zhang; Yuncheng Li; Zhengang Tang; Weijia Kong
Journal:  Tumour Biol       Date:  2013-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.